136 related articles for article (PubMed ID: 7995004)
1. Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus.
Mrozikiewicz PM; Drakoulis N; Roots I
Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 1):626-34. PubMed ID: 7995004
[TBL] [Abstract][Full Text] [Related]
2. N-acetyltransferase-2 genotypes among Jordanian patients with diabetes mellitus.
Irshaid YM; Abujbara MA; Ajlouni KM; El-Khateeb M; Jarrar YB
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):593-9. PubMed ID: 23587153
[TBL] [Abstract][Full Text] [Related]
3. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer.
Cascorbi I; Brockmöller J; Mrozikiewicz PM; Bauer S; Loddenkemper R; Roots I
Cancer Res; 1996 Sep; 56(17):3961-6. PubMed ID: 8752164
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis.
Woolhouse NM; Qureshi MM; Bastaki SM; Patel M; Abdulrazzaq Y; Bayoumi RA
Pharmacogenetics; 1997 Feb; 7(1):73-82. PubMed ID: 9110365
[TBL] [Abstract][Full Text] [Related]
5. Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals.
Bakayev VV; Mohammadi F; Bahadori M; Sheikholslami M; Javeri A; Masjedi MR; Velayati AA
Eur J Clin Pharmacol; 2004 Sep; 60(7):467-71. PubMed ID: 15316701
[TBL] [Abstract][Full Text] [Related]
6. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects.
Brocvielle H; Muret P; Goydadin AC; Boone P; Broly F; Kantelip JP; Humbert P
Skin Pharmacol Appl Skin Physiol; 2003; 16(6):386-92. PubMed ID: 14528063
[TBL] [Abstract][Full Text] [Related]
7. Diverse point mutations in the human gene for polymorphic N-acetyltransferase.
Vatsis KP; Martell KJ; Weber WW
Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6333-7. PubMed ID: 2068113
[TBL] [Abstract][Full Text] [Related]
8. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.
Cascorbi I; Drakoulis N; Brockmöller J; Maurer A; Sperling K; Roots I
Am J Hum Genet; 1995 Sep; 57(3):581-92. PubMed ID: 7668286
[TBL] [Abstract][Full Text] [Related]
9. [Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping].
Goldenkova-Pavlova IV; Bruskin SA; Abdeev RM; Markarova EV; Bigvava SG; Radkevich LA; Kozhekbaeva ZhM; Glotov AS; Gra OA; Zasedatelev AS; Nasedkina TV; Kurdanov KhA; Piruzian ES
Genetika; 2006 Aug; 42(8):1143-50. PubMed ID: 17025166
[TBL] [Abstract][Full Text] [Related]
10. Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens.
Hein DW; Doll MA; Rustan TD; Gray K; Ferguson RJ; Feng Y
Toxicol Appl Pharmacol; 1994 Jan; 124(1):16-24. PubMed ID: 8291057
[TBL] [Abstract][Full Text] [Related]
11. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
[TBL] [Abstract][Full Text] [Related]
12. Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test.
Taja-Chayeb L; González-Fierro A; Miguez-Muñoz C; Trejo-Becerril C; Cruz-Hernandez Ede L; Cantu D; Agundez JA; Vidal-Millan S; Gutierrez O; Dueñas-González A
Pharmacogenet Genomics; 2011 Dec; 21(12):894-901. PubMed ID: 21946899
[TBL] [Abstract][Full Text] [Related]
13. N-acetyltransferase-2 polymorphism, smoking and type 1 diabetic nephropathy.
Korpinen E; Groop PH; Rautio A; Madácsy L; Reunanen A; Vaarala O; Akerblom HK
Pharmacogenetics; 1999 Oct; 9(5):627-33. PubMed ID: 10591543
[TBL] [Abstract][Full Text] [Related]
14. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
15. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.
Hirvonen A; Saarikoski ST; Linnainmaa K; Koskinen K; Husgafvel-Pursiainen K; Mattson K; Vainio H
J Natl Cancer Inst; 1996 Dec; 88(24):1853-6. PubMed ID: 8961976
[TBL] [Abstract][Full Text] [Related]
16. Cloning, expression, and functional characterization of two mutant (NAT2(191) and NAT2(341/803)) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles.
Ferguson RJ; Doll MA; Rustan TD; Gray K; Hein DW
Drug Metab Dispos; 1994; 22(3):371-6. PubMed ID: 7915226
[TBL] [Abstract][Full Text] [Related]
17. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population.
Mrozikiewicz PM; Cascorbi I; Brockmöller J; Roots I
Clin Pharmacol Ther; 1996 Apr; 59(4):376-82. PubMed ID: 8612380
[TBL] [Abstract][Full Text] [Related]
18. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans.
Bell DA; Taylor JA; Butler MA; Stephens EA; Wiest J; Brubaker LH; Kadlubar FF; Lucier GW
Carcinogenesis; 1993 Aug; 14(8):1689-92. PubMed ID: 8102597
[TBL] [Abstract][Full Text] [Related]
19. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers.
Agúndez JA; Olivera M; Ladero JM; Rodriguez-Lescure A; Ledesma MC; Diaz-Rubio M; Meyer UA; Benítez J
Pharmacogenetics; 1996 Dec; 6(6):501-12. PubMed ID: 9014199
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes.
Hein DW; Ferguson RJ; Doll MA; Rustan TD; Gray K
Hum Mol Genet; 1994 May; 3(5):729-34. PubMed ID: 8081359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
